Abstract
The optimal strategy of antithrombotic therapy for patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention remains to be a question to be answered. The major challenge in such population is the balance between the benefit of reduced stroke and coronary ischemic events, against the risk of increased bleeding complications. Thus, both thrombotic and bleeding risk assessments should be included into clinical decision-making process for such patients. Currently, there is limited evidence based on randomized trials with adequate power to show the superiority of any strategy in the beneficial profile of safety and efficacy, thus limited recommendations are provided by clinical guidelines. Given the recent advancement in this field, our review provided an overview of the available risk stratification schemes for stroke and bleeding risk for AF patients, discussed the multiple questions in the optimal regimens of oral antiplatelet and anticoagulation therapy, and summarized evidence and recommendations related to long-term antithrombotic therapy for AF patients receiving stent implications.
Keywords: Antithrombotic therapy, coronary artery disease, atrial fibrillation, anticoagulants, antiplatelet therapy, percutaneous coronary intervention.
Current Pharmaceutical Design
Title:Antithrombotic Strategies in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
Volume: 24 Issue: 4
Author(s): Daorong Pan, Xiaomin Ren and Zuoying Hu*
Affiliation:
- Department of Cardiology, Nanjing Medical University Affiliated Nanjing Hospital, Nanjing Medical University, Nanjing,China
Keywords: Antithrombotic therapy, coronary artery disease, atrial fibrillation, anticoagulants, antiplatelet therapy, percutaneous coronary intervention.
Abstract: The optimal strategy of antithrombotic therapy for patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention remains to be a question to be answered. The major challenge in such population is the balance between the benefit of reduced stroke and coronary ischemic events, against the risk of increased bleeding complications. Thus, both thrombotic and bleeding risk assessments should be included into clinical decision-making process for such patients. Currently, there is limited evidence based on randomized trials with adequate power to show the superiority of any strategy in the beneficial profile of safety and efficacy, thus limited recommendations are provided by clinical guidelines. Given the recent advancement in this field, our review provided an overview of the available risk stratification schemes for stroke and bleeding risk for AF patients, discussed the multiple questions in the optimal regimens of oral antiplatelet and anticoagulation therapy, and summarized evidence and recommendations related to long-term antithrombotic therapy for AF patients receiving stent implications.
Export Options
About this article
Cite this article as:
Pan Daorong , Ren Xiaomin and Hu Zuoying *, Antithrombotic Strategies in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention, Current Pharmaceutical Design 2018; 24 (4) . https://dx.doi.org/10.2174/1381612824666171227215246
DOI https://dx.doi.org/10.2174/1381612824666171227215246 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Cichorium Intybus Linn on Blood Glucose, Lipid Constituents and Selected Oxidative Stress Parameters in Streptozotocin-Induced Diabetic Rats
Cardiovascular & Hematological Disorders-Drug Targets Oxidative Damage Impact on Aging and Age-Related Diseases: Drug Targeting of Telomere Attrition and Dynamic Telomerase Activity Flirting with Imidazole-Containing Dipeptides
Recent Patents on Drug Delivery & Formulation Neuro-Clinical Signatures of Language Impairments: A Theoretical Framework for Function-to-structure Mapping in Clinics
Current Topics in Medicinal Chemistry Therapeutic Use of Heat Shock Protein 70
Recent Patents on DNA & Gene Sequences B-lymphocytes as Targets for Therapy in Chronic Cold Agglutinin Disease
Cardiovascular & Hematological Disorders-Drug Targets Mitochondrial Dysfunction, Oxidative Stress and Diabetic Cardiovascular Disorders
Cardiovascular & Hematological Disorders-Drug Targets Flavonoids and its Neuroprotective Effects on Brain Ischemia and Neurodegenerative Diseases
Current Drug Targets Radiopharmaceuticals in Neurological and Psychiatric Disorders
Current Clinical Pharmacology Inhibitory Effect of Selective Cyclooxygenase-2 Inhibitor Etoricoxib on Human Organic Anion Transporter 3 (hOAT3)
Drug Metabolism Letters Clinical and Forensic Signs Related to Opioids Abuse
Current Drug Abuse Reviews Dietary Regulation of Glucose Metabolism in Metabolic Syndrome
Current Vascular Pharmacology Pharmacokinetics and Pharmacodynamics of Rivaroxaban – An Oral, Direct Factor Xa Inhibitor
Current Clinical Pharmacology Synthetic Approaches to the 2006 New Drugs
Mini-Reviews in Medicinal Chemistry Trimethylamine N-Oxide as a Potential Risk Factor for Non-communicable Diseases: A Systematic Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Resistance to Aspirin and Thienopyridines in Diabetes Mellitus and Metabolic Syndrome
Current Vascular Pharmacology Nanotubes at Neural and Immune Synapses
Current Medicinal Chemistry A Model on the Induction of Adverse Vascular Long-Term Effects of NSAIDs
Medicinal Chemistry Meet Our Regional Editor
Current Vascular Pharmacology Exploring the use of Estrogen & Progesterone Replacement Therapy in Subarachnoid Hemorrhage
Current Drug Safety Biobanking in Atherosclerotic Disease, Opportunities and Pitfalls
Current Cardiology Reviews